Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 02 - 04 save search
Vuzix Completes Phase 1 Development of a Customized Head Mounted Waveguide-Based Display System for Assisted Medical Cancer Surgeries
Published: 2021-02-04 (Crawled : 20:00) - biospace.com/
VUZI P | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
| O: 4.24%
H: 4.66%
C: 1.31%
cancer phase 1 phase 3 phase 2
CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma
Published: 2021-02-04 (Crawled : 20:00) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: 3.24%
H: 4.08%
C: 1.22%
cancer trial phase 1 phase 3 phase 2 program
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
Published: 2020-10-14 (Crawled : 15:10) - ir.cyclerion.com
CYCN | $3.315 12.62% 3.3K
|
Health Technology
|
| O: -42.54%
H: 3.15%
C: -18.11%
disease results phase 2
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
Published: 2021-02-04 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 1.03%
H: 1.13%
C: -1.78%
china phase 2 trial glioblastoma
ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
Published: 2021-02-04 (Crawled : 14:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 2.58%
H: 4.47%
C: 3.23%
phase 2 trial enroll
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient SettingTrial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to moderate COVID-19
Published: 2021-02-04 (Crawled : 14:00) - biospace.com/
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 0.52%
H: 2.5%
C: -7.63%
covid phase 2 trial xin sars-cov-2 at-527
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
Published: 2021-02-04 (Crawled : 13:01) - globenewswire.com
CRNX | $42.98 -0.07% -0.07% 620K
|
Health Technology
|
| O: 2.72%
H: 4.71%
C: 0.9%
renal disease phase 3 phase 1 phase 2
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
Published: 2021-02-04 (Crawled : 12:01) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 0.52%
H: 2.5%
C: -7.63%
phase 2 trial at-527 set
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.